HC Wainwright restated their buy rating on shares of Viking Therapeutics (NASDAQ:VKTX - Free Report) in a research report released on Friday,Benzinga reports. HC Wainwright currently has a $102.00 price target on the biotechnology company's stock.
VKTX has been the subject of a number of other research reports. William Blair reissued an "outperform" rating on shares of Viking Therapeutics in a research note on Wednesday, November 20th. Oppenheimer restated an "outperform" rating and set a $138.00 price objective on shares of Viking Therapeutics in a research note on Wednesday, September 25th. Piper Sandler began coverage on Viking Therapeutics in a research report on Monday, December 2nd. They set an "overweight" rating and a $74.00 price objective on the stock. StockNews.com upgraded shares of Viking Therapeutics to a "sell" rating in a report on Tuesday, October 15th. Finally, B. Riley started coverage on shares of Viking Therapeutics in a report on Friday, November 22nd. They issued a "buy" rating and a $109.00 price target on the stock. One research analyst has rated the stock with a sell rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $106.75.
View Our Latest Analysis on VKTX
Viking Therapeutics Trading Up 0.3 %
Shares of Viking Therapeutics stock traded up $0.09 during trading on Friday, hitting $32.65. 4,363,202 shares of the stock traded hands, compared to its average volume of 3,051,237. The stock's fifty day simple moving average is $46.21 and its 200 day simple moving average is $56.02. The firm has a market cap of $3.64 billion, a P/E ratio of -35.11 and a beta of 0.95. Viking Therapeutics has a 52-week low of $20.47 and a 52-week high of $99.41.
Viking Therapeutics (NASDAQ:VKTX - Get Free Report) last posted its earnings results on Wednesday, October 23rd. The biotechnology company reported ($0.22) EPS for the quarter, beating analysts' consensus estimates of ($0.24) by $0.02. During the same quarter in the previous year, the company posted ($0.23) EPS. As a group, equities analysts expect that Viking Therapeutics will post -0.97 EPS for the current year.
Insider Activity at Viking Therapeutics
In related news, Director Sarah Kathryn Rouan sold 11,000 shares of the company's stock in a transaction that occurred on Friday, October 25th. The stock was sold at an average price of $80.89, for a total value of $889,790.00. Following the sale, the director now owns 9,500 shares in the company, valued at $768,455. This represents a 53.66 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Brian Lian sold 194,490 shares of the firm's stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $42.75, for a total transaction of $8,314,447.50. Following the transaction, the chief executive officer now directly owns 2,366,570 shares of the company's stock, valued at $101,170,867.50. This represents a 7.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 443,701 shares of company stock valued at $23,898,520 in the last ninety days. Company insiders own 4.70% of the company's stock.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently added to or reduced their stakes in VKTX. Blue Trust Inc. purchased a new position in shares of Viking Therapeutics during the 3rd quarter valued at about $26,000. GAMMA Investing LLC grew its holdings in Viking Therapeutics by 124.6% during the third quarter. GAMMA Investing LLC now owns 438 shares of the biotechnology company's stock worth $28,000 after acquiring an additional 243 shares during the period. Gilliland Jeter Wealth Management LLC purchased a new position in Viking Therapeutics during the third quarter valued at approximately $32,000. Stone House Investment Management LLC lifted its holdings in Viking Therapeutics by 66.7% in the third quarter. Stone House Investment Management LLC now owns 500 shares of the biotechnology company's stock valued at $32,000 after acquiring an additional 200 shares during the period. Finally, Massmutual Trust Co. FSB ADV boosted its position in Viking Therapeutics by 84.3% in the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 553 shares of the biotechnology company's stock worth $35,000 after purchasing an additional 253 shares in the last quarter. 76.03% of the stock is currently owned by institutional investors and hedge funds.
About Viking Therapeutics
(
Get Free Report)
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
Further Reading
Before you consider Viking Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viking Therapeutics wasn't on the list.
While Viking Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
